-
ICD-10-CM Codes
›
-
Q00-Q99
›
-
Q80-Q89
›
-
Q86-
›
-
2023 ICD-10-CM Diagnosis Code Q86.1
2023 ICD-10-CM Diagnosis Code Q86.1
Fetal hydantoin syndrome
2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code POA Exempt
- Q86.1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2023 edition of ICD-10-CM Q86.1 became effective on October 1, 2022.
- This is the American ICD-10-CM version of Q86.1 - other international versions of ICD-10 Q86.1 may differ.
The following code(s) above
Q86.1 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
that may be applicable to
Q86.1:
- A rare syndrome caused by exposure of the fetus to phenytoin. It manifests with growth developmental abnormalities, cleft lip, and abnormal skull and facial characteristics.
- Multiple abnormalities in infants whose mothers were treated for epilepsy with hydantoin anticonvulsants during pregnancy. The abnormalities include disorders of growth and mental development, dysmorphic facies, and osteoarticular, cardiovascular, and other anomalies. Neoplasms complicate some cases.
Present On AdmissionPOA Help
"Present On Admission" is defined as present at the time the order for inpatient admission occurs — conditions that develop during an outpatient encounter, including emergency department, observation, or outpatient surgery, are considered POA.
- Q86.1 is considered exempt from POA reporting.
ICD-10-CM Q86.1 is grouped within Diagnostic Related Group(s) (MS-DRG v40.0):
- 794 Neonate with other significant problems
Convert Q86.1 to ICD-9-CM
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
Code annotations containing back-references to Q86.1:
ICD-10-CM Codes Adjacent To Q86.1
Q85.09 Other neurofibromatosis
Q85.8 Other phakomatoses, not elsewhere classified
Q85.83 Von Hippel-Lindau syndrome
Q85.89 Other phakomatoses, not elsewhere classified
Q85.9 Phakomatosis, unspecified
Q86 Congenital malformation syndromes due to known exogenous causes, not elsewhere classified
Q86.0 Fetal alcohol syndrome (dysmorphic)
Q86.1
Fetal hydantoin syndrome
Q86.2 Dysmorphism due to warfarin
Q86.8 Other congenital malformation syndromes due to known exogenous causes
Q87 Other specified congenital malformation syndromes affecting multiple systems
Q87.0 Congenital malformation syndromes predominantly affecting facial appearance
Q87.1 Congenital malformation syndromes predominantly associated with short stature
Q87.19 Other congenital malformation syndromes predominantly associated with short stature
Q87.2 Congenital malformation syndromes predominantly involving limbs
Q87.3 Congenital malformation syndromes involving early overgrowth
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.
